PRNewsWire
10 Jun 2026, 01:06 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's Phase III TACTI-004 trial for futility. — The failure of a Phase III trial for a primary drug candidate is a catastrophic event for a biotech company's valuation and pipeline viability.
-1.00A securities fraud class action lawsuit has been filed alleging Immutep misled investors regarding the efficacy and viability of its drug candidate. — Legal action for fraud adds significant regulatory risk and potential financial liabilities beyond the clinical failure.
-0.60Immutep's ADR price collapsed approximately 83%, falling from $2.76 to $0.48 following the futility announcement. — This confirms a massive loss of market capitalization and a severe negative shift in investor sentiment.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company faces a class action lawsuit following an 83% stock price drop after a phase III trial was discontinued for futility.
The company is the subject of a class action lawsuit filed by Robbins LLP.
The company is the subject of a class action lawsuit filed by Robbins LLP.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
12m ago
